ARTICLE | Finance
Series A to NDA
Why a series A will carry Symbiomix's antibiotic to an NDA for vaginosis
May 11, 2015 7:00 AM UTC
Symbiomix Therapeutics LLC is on track to parlay a tranched $32.5 million series A round into an NDA submission for SYM-1219, a granule formulation of secnidazole to treat bacterial vaginosis.
The first two tranches - $12.5 million in 2013 and $7 million a year later - plus an $8.5 million venture debt deal with Square 1 Bank in 2014, took the product from preclinical development to pivotal Phase II data. The company announced last week that a single dose of oral SYM-1219 met the undisclosed primary and secondary endpoints vs. placebo...